Wyeth  (WYE) Trade Now »     Rate WYE  -  Discuss WYE  -  Add to Watch List        

New Preventive Medicine Index

 

One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies together.

 

Trading the Trials and FDA Decision Calendar

 

The tables at my website links below feature an updated calendar of 80 expected FDA new product decisions and 89 pending clinical trial result estimates + pending FDA re-submissions. Click here for a link to my previous FDA calendars and click here for a list of 14 extreme trades of companies with market caps below $100M and pending new drug decisions at the FDA.

 

http://www.etfinnovators.com/2009/01/trading-trials-and-fda-d...